

CLAIMS:

1. A drug that comprises hollow nanoparticles of a particle-forming protein, that is capable of recognizing a specific cell or tissue, and is fused with a disease-treating target-cell-substance.

2. The drug as set forth in claim 1, wherein the particle-forming protein comprises a hepatitis B virus surface-antigen protein.

3. The drug as set forth in claim 1 or 2, wherein the drug is obtained by transforming an eukaryotic cell with a vector that contains a first gene encoding the particle-forming protein and a second gene, downstream of the first gene, encoding the target-cell-substance, and by expressing the first and second genes in the eukaryotic cell that has been transformed.

4. The drug as set forth in claim 3, wherein the eukaryotic cell is selected from a group consisting of a yeast cell, insect cell, and animal cell.

5. The drug as set forth in any one of claims 1 through 4, wherein the drug is used for treatment of hepatic diseases.

6. The drug as set forth in any one of claims 1 through 5, wherein the target-cell substance is an interferon or a hepatocyte growth factor.

7. The drug as set forth in any one of claims 1 through 6, wherein the drug is administered to the human body through intravenous injection.

8. A disease treating method comprising administering the drug of any one of claims 1 through 7.